tbuckley/cabot-search huggingface dataset:
SAT0273 Golimumab retention rate in patients with spondyloarthritis. differences between ankylosing spondylitis and non-radiographic axial spondyloarthritis
Authors: B. Serrano-Benavente, C.M. González Fernández, L. Valor, J.C. Nieto-González, R.D. González-Benítez, I. Janta, C. Sáenz Tenorio, J.G. Ovalles-Bonilla, J. Martínez-Barrio, M. Correyero Plaza, L. García-Montoya, F.J. López-Longo, I. Monteagudo Saez
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The efficacy of Golimumab treatment in spondyloarthritis (SpA) has been widely documented. <h3>Objectives</h3> The aim of this study was to analize the long-term retention rate of Golimumab and to identify independent predictors of retention in patients with SpA. <h3>Methods</h3> Prospective monocentric cohort of SpA patients treated with Golimumab according with clinical practice. Study was approved by local Ethics Committee. Demographic and clinical variables were analysed with Cox proportional hazard regression model. <h3>Results</h3> 105 patients were included, 49 (46.7%) Ankylosing Spondylitis (AS), 40 (38.1%) non-radiographic axial SpA (nr-AxSpA) and 16 (15,2%) peripheral SpA. The baseline characteristics of the patients are shown in table 1. Follow-up time was 206.6 patients-year. Mean survival time was 47.2 months (95% CI: 39.4–54.9). Age, gender, HLA-B27, radiographic or nr-AxSpA and previous biological use were significant in the univariate analysis. Concomitant DMARD had no influence on Golimumab retention rate (HR: 1.2; 95% CI: 0.6–2.4; p: 0.6). <h3>Conclusions</h3> Real-world Golimumab retention rate in patients with Spondyloarthritis was good and did not depend on concomitant treatment with DMARD. Patients with Ankylosing Spondylitis and non-radiographic axial SpA with objective inflammation had a better Golimumab retention rate than patients with non-radiographic axial SpA without objective inflammation. A better retention rate was expected in patients who had previously used less biological, but was not found. <h3>Disclosure of Interest</h3> None declared
GW29-e1538 Two-year safety and effectiveness of dabigatran in Asian patients with atrial fibrillation: Phase II results from Asian countries in the GLORIA-AF Registry Program
Authors: Changsheng Ma, Young Hoon Kim, Yorihiko Higashino, Evgeny V. Shlyakhto, Sergio J. Dubner, Jonathan L. Halperin, Kenneth J. Rothman, Shihai Lu, Lionel Riou Franca, Miney Paquette, Christine Teutsch, Menno V. Huisman, Gregory YH. Lip
Journal: Journal of the American College of Cardiology (2018)
CANscript™ as a patient-derived predictive platform for individualizing treatment in lung cancer
Authors: G. Babu, K. Deepak, B. Balakrishnan, M. Biswas, A. Prasath, P. Radhakrishnan, A. Chatterjee, S. Thiyagarajan, P. Chaudhuri, P.K. Majumder
Journal: Annals of Oncology (2018)
Abstract 12921: Contemporary Evaluation of Female Gender and Outcomes in Heart Failure With Reduced or Preserved Left Ventricular Systolic Function
Authors: Paniz Vafaei, Thomas K Leong, Sue Hee Sung, Keane K Lee, Alan S Go
Journal: Circulation (2016)

Introduction: How gender influences prognosis in heart failure with reduced ejection fraction (HF-REF) compared to preserved ejection fraction (HF-PEF) in contemporary populations is not well described. Hypothesis: In a representative community-based HF population, female gender is independently associated with better outcomes in HF-REF and HF-PEF. Methods: Between 2005-2012, we identified adults with confirmed HF-REF or HF-PEF receiving care in Kaiser Permanente Northern California. Outcomes included death and hospitalizations for HF or any cause. We used extended Cox regression to evaluate the impact of female gender on outcomes after accounting for baseline characteristics, cardiovascular risk factors, medical history and receipt of HF and other cardiovascular therapies based on data from comprehensive electronic health records. Results: Among 24,257 eligible adults with HF-REF or HF-PEF, 11,227 (46%) were women and 13,030 (54%) were men. At entry, women were older and more likely to have HF-PEF, hypertension, stroke/TIA, thyroid disease, depression, and low-income status. However, women were less likely to have coronary disease, peripheral arterial disease, and dyslipidemia. Compared to men, women received more calcium blockers, diuretics and NSAIDs and less aldosterone receptor blockers, statins and antiplatelet agents. Overall rates (per 100 person-years) were high for death (14.7), HF hospitalization (16.0) and any hospitalization (74.9). After adjustment for confounders and therapies received, women were less likely than men to die, a finding that was more prominent in HF-REF (adjusted HR 0.81 [0.76-0.87]) than HF-PEF (HR 0.92 [0.88-0.97]). Additionally, though women were less likely to be admitted for HF in HF-REF (HR 0.89 [0.82-0.97]), the opposite was true in HF-PEF (HR 1.09 [1.02-1.17]). No clinically meaningful adjusted difference was seen by gender for all-cause hospitalization in HF-REF or HF-PEF. Conclusions: In a large, contemporary HF population, female gender was independently associated with lower mortality in both HF-REF and HF-PEF but differential associations for HF hospitalizations by HF type. Future research is needed to understand potential gender-specific mechanisms explaining variation in outcomes.
Outbreak of Burkholderia cepacia complex infections associated with contaminated octenidine mouthwash solution, Germany, August to September 2018
Authors: Sören L. Becker, Fabian K. Berger, Susanne K. Feldner, Irem Karliova, Manfred Haber, Alexander Mellmann, Hans-Joachim Schäfers, Barbara Gärtner
Journal: Eurosurveillance (2018)

Three German patients developed nosocomial pneumonia after cardiac surgery and had Burkholderia cepacia complex detected in respiratory specimens. Two patients died of septic multi-organ failure. Whole-genome sequencing detected genetically identical B. cepacia complex strains in patient samples, from a batch of octenidine mouthwash solution, which had been used for nursing care, as well as in samples obtained from the manufacturer during production. Contamination of medical products during manufacturing may lead to international outbreaks.
Outcomes of Hospital Transfers for Pediatric Abdominal Pain and Appendicitis
Authors: Urbano L. França, Michael L. McManus
Journal: JAMA Network Open (2018)

<h3>Importance</h3> Hospital care for children is becoming more concentrated, with interhospital transfer occurring more frequently even for common conditions. Condition-specific analysis is required to determine the value, costs, and consequences of this trend. <h3>Objectives</h3> To describe the capabilities of transferring and receiving hospitals and to determine how often children transferred after an initial diagnosis of abdominal pain or appendicitis require higher levels of care. <h3>Design, Setting, and Participants</h3> Retrospective cohort analysis using the 2 most recent available inpatient and emergency department administrative data sets from all acute care hospitals in California from 2010 to 2011 and Florida, Massachusetts, and New York from 2013 to 2014. Data were analyzed between February and June 2018. All patients younger than 18 years with a primary diagnosis of abdominal pain or appendicitis who underwent an interhospital transfer and whose care could be matched through unique identifiers were included. <h3>Main Outcomes and Measures</h3> Outcomes after hospital transfers, classified into encounters with major surgical procedures, imaging diagnostics, and no major procedures. Pediatric Hospital Capability Index of transferring and receiving hospitals. <h3>Results</h3> There were 465 143 pediatric hospital encounters for abdominal pain and appendicitis, including 53 517 inpatient admissions and 15 275 transfers. Among them, 4469 could be matched to encounters in receiving hospitals. The median (interquartile range) age of this cohort was 10 (7-14) years, with 54.8% female (2449 patients), 40.9% male (1830 patients), and 4.3% unreported sex (190 patients). The increase in capability at the receiving hospital compared with the transferring hospital was large (median [interquartile range] change in Pediatric Hospital Capability Index score, 0.70 [0.54-0.82]), with 9.2% of hospitals (57) with very high capability (Pediatric Hospital Capability Index score &gt;0.77) receiving 80.8% of the total transfers (3610). Diagnostic imaging was undertaken in the care of 710 transferred patients (15.9%) and invasive procedures were performed in 2421 patients (54.2%), including 2153 appendectomies. No imaging or surgery was required in the care of 1338 transfers (29.9%). <h3>Conclusions and Relevance</h3> In this study, interfacility transfers of patients with appendicitis and abdominal pain were concentrated toward high-capability hospitals, and about 30% of patients were released without apparent intervention. These findings suggest an opportunity for improving care and decreasing cost through better interfacility coordination, such as standardized management protocols and telemedicine with high-capability hospitals. Further research is needed to identify similar opportunities among other common conditions.
Increased Prevalence of Type 2 Diabetes–Related Complications in Combined Type 2 Diabetes and Sickle Cell Trait
Authors: Sarah C. Skinner, Mor Diaw, Vincent Pialoux, Maïmouna Ndour Mbaye, Pauline Mury, Philomène Lopez, Delphine Bousquet, Fatou Gueye, Demba Diedhiou, Philippe Joly, Céline Renoux, Djiby Sow, Saliou Diop, Brigitte Ranque, Agnès Vinet, Abdoulaye Samb, Nicolas Guillot, Philippe Connes
Journal: Diabetes Care (2018)

OBJECTIVE The prevalence of type 2 diabetes (T2D) is rapidly increasing in sub-Saharan Africa, where sickle cell trait (SCT) is also frequent. Although SCT is generally considered a benign condition, evidence suggests that SCT could exaggerate vascular dysfunction in T2D. However, it remains unclear whether SCT could increase the risk of the development of T2D complications. Therefore, this study was conducted to determine whether T2D complications were more prevalent among Senegalese individuals with SCT and T2D than among those with T2D only. RESEARCH DESIGN AND METHODS Rates of hypertension, retinopathy, peripheral neuropathy, peripheral artery disease, and impaired renal function as well as arterial stiffness, blood rheology, and concentrations of plasma advanced glycation end products (AGEs) and cytokines were compared between groups of Senegalese individuals with combined SCT and T2D (T2D-SCT) (n = 60), T2D (n = 52), SCT (n = 53), and neither T2D nor SCT (control) (n = 56). Human aortic endothelial cell (HAEC) expression of inflammatory and adhesion factors was measured after treatment with tumor necrosis factor-α and subjects’ plasma. Effects of AGE inhibition or tiron on HAEC expression of E-selectin were measured. RESULTS Retinopathy, hypertension, and reduced renal function were more prevalent, and arterial stiffness, blood viscosity at high shear rates, and thixotropic index were higher, in the T2D-SCT group compared with the other groups. Multivariable analysis showed that plasma AGE concentration was significantly associated with arterial stiffness. E-selectin expression was elevated in HAECs treated with T2D-SCT plasma compared with the other groups, but AGE inhibition reversed this. CONCLUSIONS SCT could potentially augment the risk of the development of T2D-related complications, including retinopathy, nephropathy, and hypertension.
Abstract 16061: Lipoprotein(a) and Cardiovascular Risk Prediction in Women
Authors: Nancy R Cook, Paul M Ridker
Journal: Circulation (2017)

Introduction: While lipoprotein(a) [Lp(a)] is generally associated with incident cardiovascular (CV) events, controversy remains as to whether it contributes to cardiovascular risk prediction, particularly in women. We sought to examine the shape of the relationship of Lp(a) to incident CV events in women, its interaction with baseline lipids and hormone therapy (HT), and to assess its usefulness in terms of risk reclassification. Methods: Lp(a) concentration was assessed using a turbidimetric assay in three samples of women: the Women’s Health Study (WHS, N=24,558, median 10 years of follow-up), a case-cohort sample from the Women’s Health Initiative Observational Study (WHI, 1815 cases, subcohort size=1989, median 10 years of follow-up), and the Justification for Use of Statins in Prevention (JUPITER) trial (N=2,569, median 2 years of follow-up), as well as men from JUPITER (N=5,161). A derivation sample from the WHS of size 16,400 was used to determine the best functional form for Lp(a) in predicting a...
Expression of VEGF and N-cadherin in adrenal cortical cancers and a mouse xenograft model to assess possible new therapeutic targets
Authors: Irina Veytsman, John Yu, Sherry Yang, Dat Nguyen, Merrill Goldsmith, William Waud, Tito Fojo
Journal: Cancer Research (2007)

5274   Adrenocortical cancer (ACC) is a rare tumor optimally treated with surgical resection. Unfortunately in many patients tumors are not amenable to surgical resection, while others suffer a subsequent relapse, so that there is a need for more effective systemic therapies. The availability of agents directed at novel targets offers the opportunity to identify new agents with activity in ACC. The recent approval of both sunitinib and sorafenib for renal cell carcinoma offers multi-targeted kinase inhibitors that may be active in other malignancies. A putative target for these drugs is the VEGF receptor. VEGF, often produced in tumors can be secreted and can activate the VEGFR in both tumor cells and vascular endothelium. We examined VEGF expression in 16 adrenal tumors by immunohistochemistry (IHC). Compared with a p53 mutant colon cancer used as the positive control, VEGF levels were much higher in 3/16, intermediate defined as comparable to that in the colon cancer cells in an additional 10, and low in 3 ACC tumors. Analysis of HIF1α in a subset of the patients found high to very high levels of nuclear HIF1α in some providing a potential pathway for VEGF activation. N-cadherin a member of a superfamily of transmembrane proteins responsible for cell-to-cell adhesion in vertebrate is expressed predominantly in neural and mesodermal epithelia. Over-expression of N-cadherin is associated with tumor progression and metastasis in breast, prostate, lung and bladder cancer and agents targeting this pathway are in development. Little is known about the role of cadherins in ACC. The adrenal gland is composed of the cortex and medulla, arising from the mesoderm and neuroectoderm respectively. We examined expression of N-cadherin by IHC and immunoblot in 16 ACC tumors, and in H-295R cells grown  in vitro  and as xenografts with SK-N-SH neuroblastoma cells as positive control. Ki 67 a marker of proliferation was also analyzed. N-cadherin was expressed in 5/16 tumors, and 2/2 xenografts by IHC. Expression was principally membranous, but also cytoplasmic. 4/16 tumors, and 2/2 H295R xenografts were positive by immnunoblotting. There was no correlation Ki 67 and N-cadherin expression. These results show that VEGF and N-cadherin are expressed in a significant fraction of ACC and targeting these proteins may offer an alternative treatment. Studies are ongoing to determine the in vivo efficacy of agents targeting VEGF and N-cadherin using the H-295R xenograft model.
Abstract 19162: A Novel Hydrogen Sulfide Prodrug, SG-1002, Augments Angiogenesis in a Swine Model of Critical Limb Ischemia
Authors: Amanda M Rushing, Amy L Scarborough, Sarah F Boisvert, Erminia Donnarumma, Rishi Trivedi, David J Polhemus, David J Lefer, Traci T Goodchild
Journal: Circulation (2016)

Introduction: Despite advances in revascularization, treatments for critical limb ischemia (CLI) have been largely unsuccessful. Hydrogen sulfide (H2S), a gaseous signaling molecule, exerts potent ...
In primary biliary cholangitis, adding bezafibrate to ursodeoxycholic acid increased complete biochemical response
Authors: Jacob Korula
Journal: Annals of Internal Medicine (2018)

ACP Journal Club16 October 2018In primary biliary cholangitis, adding bezafibrate to ursodeoxycholic acid increased complete biochemical responseJacob Korula, MD,FACPJacob Korula, MD,FACPGastroenterology, Liver Diseases, and Transplantation, Arcadia, California, USA (J.K.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2018-169-8-045 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationCorpechot C, Chazouillères O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378:2171-81. https://pubmed.ncbi.nlm.nih.gov/29874528Clinical Impact RatingsGIM/FP/GP: Gastroenterology: References1 Nevens F, Andreone P, Mazzella G, et al; POISE Study Group. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631-43. [PMID: 27532829] Google Scholar2 Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology. 2015;62:635-43. [PMID: 25678132] Google Scholar3 Zhang Y, Li S, He L, et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. Drug Des Devel Ther. 2015;9:2757-66. [PMID: 26045661] Google Scholar4 Yin Q, Li J, Xia Y, et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis. Drug Des Devel Ther. 2015;9:5407-19. [PMID: 26491252] Google Scholar Author, Article, and Disclosure InformationAffiliations: Gastroenterology, Liver Diseases, and Transplantation, Arcadia, California, USA (J.K.)This article was published at Annals.org on 2 October 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 16 October 2018Volume 169, Issue 8Page: JC45KeywordsAminotransferasesBileBilirubinFatigueLiver diseasesPatientsPhosphatasesPruritusSafetyStiffness ePublished: 16 October 2018 Issue Published: 16 October 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Abstract 19715: Diabetes Abrogates the Cardioprotective Effects of Ischemic Postconditioning Cardioprotection by Impairing AdipoR1/Caveolin-3/STAT3 Signaling
Authors: Haobo Li, Weifeng Yao, Zipeng Liu, Sheng Wang, Michael G Irwin, Zhengyuan Xia
Journal: Circulation (2015)

Introduction: Ischemic postconditioning (IPo) protects against myocardial ischemia reperfusion (MI/R) injury by activating mitochondrial signal transducer and activator of transcription 3 (mitoSTAT3) through adiponectin (APN) in non-diabetes, but losses its effectiveness in diabetes whose cardiac APN is reduced. We postulated that malfunction of APN is the key mechanism whereby IPo losses cardioprotection in diabetes. Methods and Results: Four-week (4w) or eight-week (8w) streptozotocin-induced diabetic rats were treated with APN adenovirus (tail vein injection, 1*109 pfu) 1-week before inducing MI/R (30 minutes of left coronary artery ligation followed by 2 hours of reperfusion) with or without IPo (3 cycles of 10s of ischemia and 10s of reperfusion, n=6 per group). At the end of reperfusion, myocardial injury was more severe in both 4w and 8w diabetic rats evidenced as increased infarct size than age-matched control (43.4±3.3 in 4w diabetic vs. 30.6±2.2 in control, 55.4±2.0 in 8w diabetic vs. 38.0±1.9 in control, all P&lt;0.05) concomitant with increased plasma CK-MB release and worse cardiac function (lower dP/dtmax and ejection fraction), and more severely impaired mitochondrial function (decrease in complex I, II+III, and IV activities), more severe reduction of activated mitoSTAT3 and colocolization of APN receptor-1(AdipoR1) and caveolin-3(Cav3), a molecule essential for APN signaling. These changes cannot be reversed by IPo alone in both 4w and 8w diabetic rats, while IPo in combination with APN significantly attenuated all the abovementioned changes in 4w diabetic but not in 8w diabetic rats whose baseline and post-ischemic cardiac AdipoR1 and Cav3 expression were more severely reduced than that in 4 w diabetic rats. The protective effects of joint IPo and APN treatment in 4w diabetes were abolished by inhibition of STAT3 irrespectiove of IPo and APN induced enhancement of AdipoR1 and Cav3 expression and colocalization. Conclusion: IPo loses cardioprotection in diabetes due to reduced APN and impaired AdipoR1/Cav3 signaling. APN supplementation by activating mitoSTAT3 restores IPo cardioprotection in 4w diabetic where AdipoR1 and Cav3 are functionally interactive, but not in 8w diabetic rats whose AdipoR1/Cav3 signaling impaired.
Abstract 19397: Factors Affecting Exercise Capacity in Diabetic Heart Failure Patients
Authors: Laura N Allen, Haqeel A Jamil, John Gierula, Maria Paton, Jack Garnham, Mark Kearney, Scott Bowen, Klaus K Witte
Journal: Circulation (2015)

Background: Exercise intolerance is a key feature of chronic heart failure (CHF). CHF patients with concomitant diabetes (CHF-DM) have heightened exercise intolerance, poorer prognosis and worse symptoms. Causative mechanisms may be impaired ventilatory, cardiac or skeletal muscle function. We prospectively assessed factors affecting exercise capacity in CHF and CHF-DM. Methods: Stable CHF (n=33) and CHF-DM (n=33) patients with left ventricular systolic dysfunction (ejection fraction (EF) &lt;50%; NYHA class I-II; optimal device and medical therapy), were matched for age (mean±SD: 76±7 yr), weight (85±13 kg), height (1.72±0.06 m), systolic function (EF: 38±11%) and diastolic function (EA ratio 0.9±0.2). They underwent peak cardiopulmonary exercise testing with breath-by-breath pulmonary gas exchange analysis. Exertional shortness of breath (S) symptoms were recorded using the standardized Borg 0-10 scale. Continuous variables were reported as means (SD) and analysed using ANCOVA, categorical variables were analysed using the chi-squared test. A p-value of &lt; 0.05 was taken as significant. Results: CHF-DM had reduced exercise capacity (pVO2 13.9±4.3 v 17.5±5.9 ml/kg/min; p=0.01) and lower exercise time (354±209 v 511±250s; p=0.01). Cardiac and ventilatory responses did not differ: Heart rate rise (44±5 v 46±4 bpm; p=0.21), Ve/VCO2 (37.2±9.4 v 39.5±10.5; p=0.35), peak respiratory frequency (31.7± 6.7 v 31.1± 7.6 breaths/min; p=0.76). Symptoms did not differ at baseline, peak or during exercise (Peak Borg S: 4±2 v 4±2; p= 0.73) The lactate threshold (LT) (9.86±0.27 v 11.26 ±0.32 L/min; p=0.48), time to LT (358 ± 92.58 v 393 ± 203.94 s; p=0.22) and the respiratory compensation point (RCP) (12.77±0.37 v 14.37± 0.45 L/min; p=0.64) did not differ. Conclusion: Exercise capacity is reduced in CHF-DM subjects matched for age, BMI and cardiac function. There are no differences in symptoms of breathlessness, Ve/VCO2 slope or respiratory rate. However, LT and time to LT is unchanged, despite lower exercise time overall. Thus, there is an inability to tolerate exercise beyond the LT. This is likely due to altered skeletal mitochondrial function in the context of concomitant diabetes.
Liposomal formulation of hypoxia activated prodrug for the treatment of ovarian cancer
Authors: Vidhi M. Shah, Duc X. Nguyen, Adel Al Fatease, Pragnesh Patel, Brianna Cote, Yeonhee Woo, Rohi Gheewala, Yvonne Pham, Man Gia Huynh, Christen Gannett, Deepa A. Rao, Adam W.G. Alani
Journal: Journal of Controlled Release (2018)
Cribriform Subtype is an Independent Predictor of Recurrence and Survival After Adjustment for the Eighth Edition of TNM Staging System in Patients With Resected Lung Adenocarcinoma
Authors: Kyuichi Kadota, Yoshio Kushida, Seiko Kagawa, Ryou Ishikawa, Emi Ibuki, Kosuke Inoue, Tetsuhiko Go, Hiroyasu Yokomise, Tomoya Ishii, Norimitsu Kadowaki, Reiji Haba
Journal: Journal of Thoracic Oncology (2018)
Docetaxel, cisplatin and fluorouracil as neoadjuvant chemotherapy for esophageal cancer with prophylactic pegfilgrastim
Authors: Osamu Maeda, Masahiko Koike, Masahide Fukaya, Kazushi Miyata, Naoki Iwata, Masato Nagino, Yasuhiro Kodera, Yuichi Ando
Journal: Annals of Oncology (2018)